A phase I, first-in-human study of TAK-164, an antibody–drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C

PURPOSE: Guanylyl cyclase C (GCC) is highly expressed in several gastrointestinal malignancies and preclinical studies suggest that it is a promising target for antibody-based therapeutics. This phase I trial assessed the safety and tolerability of TAK-164, an investigational, anti-GCC antibody–drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Richard, Leal, Alexis D., Parikh, Aparna, Ryan, David P., Wang, Shining, Bahamon, Brittany, Gupta, Neeraj, Moss, Aaron, Pye, Joanna, Miao, Harry, Inguilizian, Haig, Cleary, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068631/
https://www.ncbi.nlm.nih.gov/pubmed/36738333
http://dx.doi.org/10.1007/s00280-023-04507-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068631/
https://www.ncbi.nlm.nih.gov/pubmed/36738333
http://dx.doi.org/10.1007/s00280-023-04507-w

Ejemplares similares